ArticleChildren (Basel, Switzerland)2021
MAFLD in Obese Children: A Challenging Definition.
Article in Children (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Liver Injury Biomarkers in Pediatric Metabolic Syndrome: Key Biochemical Associations.Metabolites · 2026Article
- Not Only Metabolic Complications of Childhood Obesity.Nutrients · 2024Review
- The Intersection of Genetic Factors, Aberrant Nutrient Metabolism and Oxidative Stress in the Progression of Cardiometabolic Disease.Antioxidants (Basel, Switzerland) · 2024Review
- Kidney damage predictors in children with metabolically healthy and metabolically unhealthy obesity phenotype.International journal of obesity (2005) · 2023Article
- Shaping the future of pediatric liver health: unraveling the impact of the new metabolic-associated fatty liver disease definition.Hepatobiliary surgery and nutrition · 2023Article
- Is Metabolic Syndrome Useful for Identifying Youths with Obesity at Risk for NAFLD?Children (Basel, Switzerland) · 2023Article
- Fatty liver disease in children (MAFLD/PeFLD Type 2): unique classification considerations and challenges.Therapeutic advances in endocrinology and metabolism · 2023Review
- Uric acid versus metabolic syndrome as markers of fatty liver disease in young people with overweight/obesity.Diabetes/metabolism research and reviews · 2022Article
- Metabolic-associated fatty liver disease from childhood to adulthood: State of art and future directions.World journal of hepatology · 2022Review
- Advances in pediatric non-alcoholic fatty liver disease: From genetics to lipidomics.World journal of clinical pediatrics · 2022Review
- Metabolic dysfunction is associated with steatosis but no other histologic features in nonalcoholic fatty liver disease.World journal of clinical cases · 2022Article
- Stratification by Non-invasive Biomarkers of Non-alcoholic Fatty Liver Disease in Children.Frontiers in pediatrics · 2022Article
- Triglyceride to high-density lipoprotein cholesterol ratio is an independent predictor of liver fibrosis among pediatrics non-alcoholic fatty liver disease.Frontiers in endocrinology · 2022Article
- Metabolic Fatty Liver Disease in Children: A Growing Public Health Problem.Biomedicines · 2021Review
- Association between Hepatic Steatosis and Obstructive Sleep Apnea in Children and Adolescents with Obesity.Children (Basel, Switzerland) · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecently, the new definition of Metabolic (dysfunction) associated fatty liver disease (MAFLD) has gained remarkable scientific interest. We aimed to evaluate the effectiveness of MAFLD definition in selecting obese children at higher cardiovascular risk.
methodsA total of 954 obese children and adolescents was retrospectively enrolled. Clinical, biochemical, and metabolic evaluations were performed. Hepatic steatosis was assessed by liver ultrasound. According to the metabolic status, the population was divided in three groups. Group 1 included obese patients without both non-alcoholic fatty liver disease (NAFLD) and metabolic dysregulation; group 2 included patients with obesity and NAFLD (then encompassing one MAFLD criterion); group 3 included patients with obesity, NAFLD and evidence of metabolic dysregulation (then encompassing more than 1 MAFLD criteria).
resultsPatients of Group 3 showed a worse cardiometabolic profile, as also proven by the higher percentage of prediabetes (defined as the presence of impaired fasting glucose or impaired glucose tolerance) compared to other groups (
conclusionsMAFLD criteria in obese children seem to be less accurate in identifying patients having an intrinsic higher cardiometabolic risk. This suggests the need for a more accurate definition in the context of pediatric obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.